- Market Capitalization, $K 117,801,624
- Shares Outstanding, K 2,494,212
- Annual Sales, $ 41,140 M
- Annual Income, $ 4,836 M
- 60-Month Beta 0.68
- Price/Sales 3.08
- Price/Cash Flow 11.50
- Price/Book 5.36
|Period||Period Low||Period High||Performance|
| || |
+0.33 (+0.70%)since 12/24/19
| || |
+3.21 (+7.29%)since 10/24/19
| || |
+8.86 (+23.09%)since 01/24/19
Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
The is segmented on the lines of its drug type, route of administration and regional. Basis of drug type is segmented into Acyclovir, Valacyclovir and Famciclovir. Based on route of administration it...
Global share consists of several players including Pacific World Corporation, Revitol Corporation Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Novartis AG, Renovo Group plc., Valeant Pharmaceuticals...
A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...
-- Biologics License Application based on results from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) in heavily pre-treated patient population who was refractory...
The Southeast Asia Dietary Supplements Market size is set to reach USD 10.60 billion by 2026, exhibiting a CAGR of 5.60% during the forecast period. Increasing prevalence of lifestyle-induced disorders,...
Big Market Research has added a report, titled, “” The report not only provides a comprehensive analysis of market overview and dynamics for the historical period, 2019-2026, but also offers global...